Industry U.S. FDA issues two observations to Cipla arm InvaGen’s U.S. facility February 10, 2026 gopalkumarthakur@gmail.com The observations followed a pre-approval inspection (PAI) by the regulator at InvaGen’s manufacturing facility in Hauppauge, Long Island, New York Related posts: AI algorithms can detect vision problems years before they actually appear, says ZEISS India Survey reveals the dark side of loan recovery in India Vodafone Idea outlines dues repayment plan, caps annual payouts Refining margins would have been higher had contamination incident not happened: HPCL CMD
